Heartflow (NASDAQ:HTFL) Price Target Cut to $35.00 by Analysts at Wells Fargo & Company

Heartflow (NASDAQ:HTFL) had its price target lowered by Wells Fargo & Company from $38.00 to $35.00 in a report published on Thursday,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other research firms have also recently weighed in on HTFL. Weiss Ratings restated a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. Canaccord Genuity Group reiterated a “buy” rating and issued a $40.00 price objective on shares of Heartflow in a report on Monday, March 9th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $37.67.

Heartflow Stock Up 1.6%

Shares of HTFL stock opened at $25.89 on Thursday. Heartflow has a twelve month low of $20.13 and a twelve month high of $41.22. The stock’s fifty day simple moving average is $27.01 and its 200 day simple moving average is $30.45. The firm has a market capitalization of $2.20 billion and a P/E ratio of -14.30.

Insider Buying and Selling

In other news, CEO John C.M. Farquhar sold 12,837 shares of the company’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $22.66, for a total value of $290,886.42. Following the sale, the chief executive officer directly owned 581,450 shares of the company’s stock, valued at approximately $13,175,657. This represents a 2.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Campbell Rogers sold 65,153 shares of the stock in a transaction on Thursday, February 12th. The stock was sold at an average price of $24.49, for a total transaction of $1,595,596.97. Following the sale, the insider owned 76,034 shares of the company’s stock, valued at approximately $1,862,072.66. This trade represents a 46.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 2,117,674 shares of company stock valued at $59,052,646.

Institutional Trading of Heartflow

Institutional investors have recently bought and sold shares of the company. XXEC Inc. lifted its position in shares of Heartflow by 40.5% during the 4th quarter. XXEC Inc. now owns 41,920 shares of the company’s stock valued at $1,222,000 after acquiring an additional 12,088 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in Heartflow in the fourth quarter worth $72,000. Invesco Ltd. increased its stake in Heartflow by 463.9% in the fourth quarter. Invesco Ltd. now owns 577,397 shares of the company’s stock valued at $16,831,000 after purchasing an additional 475,004 shares in the last quarter. XTX Topco Ltd raised its holdings in shares of Heartflow by 282.6% during the fourth quarter. XTX Topco Ltd now owns 43,205 shares of the company’s stock valued at $1,259,000 after purchasing an additional 31,913 shares during the period. Finally, VARCOV Co. bought a new position in shares of Heartflow during the 4th quarter worth about $1,657,000.

Trending Headlines about Heartflow

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Q4 revenue beat and strong growth — HeartFlow reported Q4 revenue of $49.13M (vs. $46.58M consensus) and year-over-year revenue growth of ~40.5%, a key driver for optimism about adoption and recurring revenue. Earnings Release / Transcript
• Positive Sentiment: Canaccord raised its price target to $43 and maintained a Buy rating — this is a constructive analyst signal that implies sizeable upside from current levels and likely supported the intraday gain. Canaccord Raise (Benzinga)
• Positive Sentiment: Longer-term growth narrative—coverage noting HeartFlow as an AI/advanced-imaging beneficiary may be underpinning investor interest in the stock’s growth prospects. AI Beneficiary Article (MSN)
• Neutral Sentiment: Analyst & research coverage continues — independent write-ups and the full earnings call transcript provide more detail for investors to reassess forecasts and growth assumptions. Seeking Alpha Analysis Earnings Call Transcript
• Negative Sentiment: EPS miss and analyst target trims — Q4 EPS was ($0.29) vs. consensus ($0.16), a notable downside vs. expectations that tempers the revenue beat. Separately, JPMorgan and Wells Fargo trimmed price targets (both to $35) though kept overweight ratings, reducing some upside implied by prior targets. Earnings Details (MarketBeat) JPMorgan / Wells Fargo Notes (Benzinga)

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.